CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time.

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...

NSCLC: Initiated randomized clinical trial (RCT) ResQ201A with N-803 + tislelizumab in 2 nd line lung cancer; US sites initiated, submitted clinical trial applications in EU, UK; Canada and Asia ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that OncoDaily has recognized Dr.

We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...

ImmunityBio has traded future profits for cash to kick off commercialization of its near-approval cancer drug candidate. Oberland Capital took the other side of the deal, handing the biotech $210 ...

ImmunityBio, Inc. (NASDAQ:IBRX) is among the best NASDAQ stocks under $10 to buy. On December 15, Edward Tenthoff, an analyst at Piper Sandler, maintained a ‘Buy’ rating on ImmunityBio, Inc.

Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its bladder cancer med is still one to watch as it competes with heavy hitters ...

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...

We recently published a list of Top 10 Penny Stocks That Will Skyrocket. In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other best stocks to penny ...

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced preliminary financial results for the fiscal quarter ended June 30, 2025, and clinical progress across its pipeline.